Walleye Capital LLC purchased a new position in shares of Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 30,465 shares of the company's stock, valued at approximately $719,000. Walleye Capital LLC owned about 0.33% of Sanara MedTech as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets lifted its stake in shares of Sanara MedTech by 351.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company's stock valued at $48,000 after purchasing an additional 1,171 shares during the last quarter. Wells Fargo & Company MN increased its position in Sanara MedTech by 78.1% during the fourth quarter. Wells Fargo & Company MN now owns 3,322 shares of the company's stock worth $78,000 after buying an additional 1,457 shares during the last quarter. Lazard Asset Management LLC raised its holdings in Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company's stock valued at $89,000 after buying an additional 3,155 shares in the last quarter. Deutsche Bank AG raised its holdings in Sanara MedTech by 171.1% during the fourth quarter. Deutsche Bank AG now owns 3,985 shares of the company's stock valued at $93,000 after buying an additional 2,515 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Sanara MedTech by 44.1% during the third quarter. Bank of America Corp DE now owns 3,181 shares of the company's stock valued at $101,000 after buying an additional 973 shares in the last quarter. Institutional investors own 8.10% of the company's stock.
Analyst Ratings Changes
Several analysts have recently issued reports on SMTI shares. Zacks Research upgraded Sanara MedTech from a "strong sell" rating to a "hold" rating in a research note on Wednesday, June 10th. Weiss Ratings raised Sanara MedTech from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday. Wall Street Zen lowered Sanara MedTech from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 1st. Lake Street Capital cut Sanara MedTech from a "buy" rating to a "hold" rating and set a $35.00 target price for the company. in a research report on Thursday, July 30th. Finally, HC Wainwright downgraded Sanara MedTech from a "buy" rating to a "neutral" rating and lowered their price target for the company from $36.00 to $35.00 in a report on Thursday, July 30th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Reduce" and a consensus target price of $35.00.
View Our Latest Research Report on SMTI
Sanara MedTech Trading Down 0.0%
Shares of NASDAQ:SMTI opened at $34.15 on Friday. The company has a debt-to-equity ratio of 5.86, a quick ratio of 2.05 and a current ratio of 2.58. The stock's 50-day moving average is $26.40 and its 200-day moving average is $22.15. The company has a market cap of $313.84 million, a P/E ratio of -9.51 and a beta of 1.13. Sanara MedTech Inc. has a 52-week low of $16.05 and a 52-week high of $35.95.
Sanara MedTech (NASDAQ:SMTI - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The business had revenue of $28.14 million for the quarter, compared to the consensus estimate of $28.95 million. Sanara MedTech had a negative net margin of 29.15% and a positive return on equity of 29.72%. Equities research analysts predict that Sanara MedTech Inc. will post 0.16 earnings per share for the current year.
Sanara MedTech Company Profile
(
Free Report)
Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company's core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.
With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.
Read More
Want to see what other hedge funds are holding SMTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanara MedTech Inc. (NASDAQ:SMTI - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Sanara MedTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanara MedTech wasn't on the list.
While Sanara MedTech currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
